Method for determining the concentration of the adipocytic form of the fatty acid binding protein (a-fabp, fabp4, p2)

Abstract

Products and methods for the research, diagnosis, risk assessment, course monitoring, treatment and prophylaxis of various metabolic disorders and their early forms, concomitant diseases and secondary diseases are provided. Metabolic diseases include, for example, metabolic syndrome, non-insulin-dependent diabetes, (type II diabetes), insulin resistance, obesity (adiposis), in addition to diseases that are associated with disorders of the fatty acid metabolism. Methods may include analysis of the concentration of the adipocytic form of the fatty acid binding protein (A-FABP, FABP 4, P2) in various bodily fluids.

1 . A test kit for the diagnosis of metabolic syndrome, of its preliminary stages, early forms, concomitant and secondary diseases, type II diabetes, insulin resistance, obesity or related disorders of the metabolism, wherein the concentration of the adipocytic form of the fatty acid binding protein (A-FABP) in bodily fluids is determined and is used as an indicator for the fatty acid transport capacity, comprising:
 a suitable carrier material on which substances with affinity to A-FABP or parts thereof have been immobilised.   
     
     
         2 . The test kit of  claim 1 , wherein the immobilised substances with affinity to A-FABP or parts thereof are manifested as antibodies. 
     
     
         3 . The test kit of  claim 1 , wherein the carrier material has at least a partly planar surface. 
     
     
         4 . The test kit of  claim 1 , wherein the carrier material is encompassed by an ELISA plate. 
     
     
         5 . The test kit of  claim 1 , wherein the test kit contains carrier material, substances and solutions suited for the implementation of an ELISA or a comparable dye assay. 
     
     
         6 . The test kit of  claim 5 , wherein the test kit contains anti-A-FABP antibodies, secondary detection antibodies, carrier materials, washing, incubation and detection solutions. 
     
     
         7 . The test kit of  claim 5 , wherein the test kit contains at least one calibration solution containing recombinant A-FABP. 
     
     
         8 . The test kit of  claim 6 , wherein the test kit contains at least one calibration solution containing recombinant A-FABP.